- Home
- All Stock List
- NSE
- Biocon Ltd Share Price
318.85
-2.00 (-0.62%)
-
Underperforms Index
6.8%
Return (1Y)
Underperformed Nifty Pharma by 6.71%
-
More Volatile
2.42%
Standard Deviation (1Y)
Higher than Nifty Pharma by 1.3%
-
Not so consistent
5/12
Months
underperformed Nifty Pharma
-
AxisDirect View
405
270
News & Announcements
-
Biocon?s board OKs to raise Rs 4,500-cr
6 days ago
?Raising of funds by way of issuance any instrument or security, including equity shares, non-convertible debt instruments along with warrants, any other convertible securities or any other eligible securities or any combination thereof by way of qualified institutions placement(s), rights issue, preferential allotment or private placement(s) and/or any combination thereof or any other method as may be permitted under applicable laws, and on such terms and conditions as may be considered appropriate by the board in its absolute discretion under applicable laws, for an aggregate amount of up to Rs 4,500 crore, in one or more tranches and/or one or more issuances, subject to the receipt of necessary approvals including approval of the shareholders of the company and other regulatory / statutory approvals,? it stated in exchange filing.
Meanwhile, the company?s board also approved to increase authorized share capital from existing Rs 625 crore divided into 125 crore equity shares of Rs 5 each to Rs 700 crore divided into 140 crore equity shares of Rs 5 each, subject to the receipt of necessary approvals including approval of the shareholders of the company and other regulatory / statutory approvals.
Biocon is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets.
The company?s consolidated net profit declined 96.2% to Rs 25.10 crore in Q3 FY25 as compared with Rs 660 crore in Q3 FY24. Net sales increased 6.3% to Rs 3773 crore in Q3 FY25.
The counter rose 0.57% to end at Rs 335.85 on Wednesday, 23 April 2025.
Powered by Capital Market - Live News
-
The Board of Biocon at its meeting held on 23 April 2025 has approved raising of funds up to Rs 4,500 crore by way of issue of securities, in one or more tranches.
The Board also approved increase in authorised share capital from Rs 625 crore to Rs 700 crore (dividend into 1,40,00,00,000 equity shares of Rs 5 each).
Powered by Capital Market - Live News
-
Biocon to consider fund Raising
9 days ago
-
The Board of Biocon at its meeting held on 23 April 2025 has approved raising of funds up to Rs 4,500 crore by way of issue of securities, in one or more tranches.
The Board also approved increase in authorised share capital from Rs 625 crore to Rs 700 crore (dividend into 1,40,00,00,000 equity shares of Rs 5 each).
Powered by Capital Market - Live News
-
Biocon to consider fund Raising
9 days ago
-
Yesafili, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for treating a range of ophthalmology conditions. The biosimilar references Regeneron's blockbuster drug EYLEA, a widely prescribed treatment in the U.S. for retinal diseases.
As part of the settlement, Biocon Biologics and Regeneron agreed to dismiss ongoing litigation related to U.S. patent no. US11084865. This includes the pending appeal at the United States Court of Appeals for the Federal Circuit and the case in the U.S. District Court for the Northern District of West Virginia, Clarksburg Division.
While the financial and commercial terms of the settlement remain confidential, the agreement enables Biocon Biologics to potentially commercialize Yesafili in the U.S. starting in the second half of 2026?or earlier, depending on certain conditions.
The company has also secured a Canadian launch deal for Yesafili no later than 1 July 2025.
Shreehas Tambe, CEO & managing director, Biocon Biologics, said: This settlement clears the path for Biocon Biologics to be among the first to bring a reliable, high-quality aflibercept biosimilar to patients and healthcare providers in the United States. As the first-to-file interchangeable biosimilar to Eylea, YESAFILI affirms our scientific strength and marks our strategic entry into Ophthalmology, expanding our footprint in the U.S. and advancing our mission to increase access to life-changing treatments.
Biocon is an innovation-led global biopharmaceuticals company. On a consolidated basis, its net profit slumped 96.20% to Rs 25.10 crore while net sales rose 6.32% to Rs 3773 crore in Q3 December 2024 over Q3 December 2023.
Powered by Capital Market - Live News
-
Biocon?s board OKs to raise Rs 4,500-cr
6 days ago
?Raising of funds by way of issuance any instrument or security, including equity shares, non-convertible debt instruments along with warrants, any other convertible securities or any other eligible securities or any combination thereof by way of qualified institutions placement(s), rights issue, preferential allotment or private placement(s) and/or any combination thereof or any other method as may be permitted under applicable laws, and on such terms and conditions as may be considered appropriate by the board in its absolute discretion under applicable laws, for an aggregate amount of up to Rs 4,500 crore, in one or more tranches and/or one or more issuances, subject to the receipt of necessary approvals including approval of the shareholders of the company and other regulatory / statutory approvals,? it stated in exchange filing.
Meanwhile, the company?s board also approved to increase authorized share capital from existing Rs 625 crore divided into 125 crore equity shares of Rs 5 each to Rs 700 crore divided into 140 crore equity shares of Rs 5 each, subject to the receipt of necessary approvals including approval of the shareholders of the company and other regulatory / statutory approvals.
Biocon is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets.
The company?s consolidated net profit declined 96.2% to Rs 25.10 crore in Q3 FY25 as compared with Rs 660 crore in Q3 FY24. Net sales increased 6.3% to Rs 3773 crore in Q3 FY25.
The counter rose 0.57% to end at Rs 335.85 on Wednesday, 23 April 2025.
Powered by Capital Market - Live News
-
The Board of Biocon at its meeting held on 23 April 2025 has approved raising of funds up to Rs 4,500 crore by way of issue of securities, in one or more tranches.
The Board also approved increase in authorised share capital from Rs 625 crore to Rs 700 crore (dividend into 1,40,00,00,000 equity shares of Rs 5 each).
Powered by Capital Market - Live News
-
Biocon to consider fund Raising
9 days ago
-
Yesafili, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for treating a range of ophthalmology conditions. The biosimilar references Regeneron's blockbuster drug EYLEA, a widely prescribed treatment in the U.S. for retinal diseases.
As part of the settlement, Biocon Biologics and Regeneron agreed to dismiss ongoing litigation related to U.S. patent no. US11084865. This includes the pending appeal at the United States Court of Appeals for the Federal Circuit and the case in the U.S. District Court for the Northern District of West Virginia, Clarksburg Division.
While the financial and commercial terms of the settlement remain confidential, the agreement enables Biocon Biologics to potentially commercialize Yesafili in the U.S. starting in the second half of 2026?or earlier, depending on certain conditions.
The company has also secured a Canadian launch deal for Yesafili no later than 1 July 2025.
Shreehas Tambe, CEO & managing director, Biocon Biologics, said: This settlement clears the path for Biocon Biologics to be among the first to bring a reliable, high-quality aflibercept biosimilar to patients and healthcare providers in the United States. As the first-to-file interchangeable biosimilar to Eylea, YESAFILI affirms our scientific strength and marks our strategic entry into Ophthalmology, expanding our footprint in the U.S. and advancing our mission to increase access to life-changing treatments.
Biocon is an innovation-led global biopharmaceuticals company. On a consolidated basis, its net profit slumped 96.20% to Rs 25.10 crore while net sales rose 6.32% to Rs 3773 crore in Q3 December 2024 over Q3 December 2023.
Powered by Capital Market - Live News
-
Biocon?s board OKs to raise Rs 4,500-cr
6 days ago
?Raising of funds by way of issuance any instrument or security, including equity shares, non-convertible debt instruments along with warrants, any other convertible securities or any other eligible securities or any combination thereof by way of qualified institutions placement(s), rights issue, preferential allotment or private placement(s) and/or any combination thereof or any other method as may be permitted under applicable laws, and on such terms and conditions as may be considered appropriate by the board in its absolute discretion under applicable laws, for an aggregate amount of up to Rs 4,500 crore, in one or more tranches and/or one or more issuances, subject to the receipt of necessary approvals including approval of the shareholders of the company and other regulatory / statutory approvals,? it stated in exchange filing.
Meanwhile, the company?s board also approved to increase authorized share capital from existing Rs 625 crore divided into 125 crore equity shares of Rs 5 each to Rs 700 crore divided into 140 crore equity shares of Rs 5 each, subject to the receipt of necessary approvals including approval of the shareholders of the company and other regulatory / statutory approvals.
Biocon is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets.
The company?s consolidated net profit declined 96.2% to Rs 25.10 crore in Q3 FY25 as compared with Rs 660 crore in Q3 FY24. Net sales increased 6.3% to Rs 3773 crore in Q3 FY25.
The counter rose 0.57% to end at Rs 335.85 on Wednesday, 23 April 2025.
Powered by Capital Market - Live News
-
The Board of Biocon at its meeting held on 23 April 2025 has approved raising of funds up to Rs 4,500 crore by way of issue of securities, in one or more tranches.
The Board also approved increase in authorised share capital from Rs 625 crore to Rs 700 crore (dividend into 1,40,00,00,000 equity shares of Rs 5 each).
Powered by Capital Market - Live News
-
Biocon to consider fund Raising
9 days ago
-
The Board of Biocon at its meeting held on 23 April 2025 has approved raising of funds up to Rs 4,500 crore by way of issue of securities, in one or more tranches.
The Board also approved increase in authorised share capital from Rs 625 crore to Rs 700 crore (dividend into 1,40,00,00,000 equity shares of Rs 5 each).
Powered by Capital Market - Live News
-
Biocon to consider fund Raising
9 days ago
-
Yesafili, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for treating a range of ophthalmology conditions. The biosimilar references Regeneron's blockbuster drug EYLEA, a widely prescribed treatment in the U.S. for retinal diseases.
As part of the settlement, Biocon Biologics and Regeneron agreed to dismiss ongoing litigation related to U.S. patent no. US11084865. This includes the pending appeal at the United States Court of Appeals for the Federal Circuit and the case in the U.S. District Court for the Northern District of West Virginia, Clarksburg Division.
While the financial and commercial terms of the settlement remain confidential, the agreement enables Biocon Biologics to potentially commercialize Yesafili in the U.S. starting in the second half of 2026?or earlier, depending on certain conditions.
The company has also secured a Canadian launch deal for Yesafili no later than 1 July 2025.
Shreehas Tambe, CEO & managing director, Biocon Biologics, said: This settlement clears the path for Biocon Biologics to be among the first to bring a reliable, high-quality aflibercept biosimilar to patients and healthcare providers in the United States. As the first-to-file interchangeable biosimilar to Eylea, YESAFILI affirms our scientific strength and marks our strategic entry into Ophthalmology, expanding our footprint in the U.S. and advancing our mission to increase access to life-changing treatments.
Biocon is an innovation-led global biopharmaceuticals company. On a consolidated basis, its net profit slumped 96.20% to Rs 25.10 crore while net sales rose 6.32% to Rs 3773 crore in Q3 December 2024 over Q3 December 2023.
Powered by Capital Market - Live News
Stock Trivia
Biocon Ltd has the Lowesr P/E ratio according to FY 202403 data among stocks in Pharmaceuticals Sector
Biocon Ltd has the Lowesr P/B ratio according to FY 202403 data among stocks in Pharmaceuticals Sector
Biocon Ltd has the Lowesr P/E ratio according to FY 202403 data among stocks in Pharmaceuticals Sector
Biocon Ltd has the Lowesr P/B ratio according to FY 202403 data among stocks in Pharmaceuticals Sector
Biocon Ltd has the Lowesr P/E ratio according to FY 202403 data among stocks in Pharmaceuticals Sector
Biocon Ltd has the Lowesr P/B ratio according to FY 202403 data among stocks in Pharmaceuticals Sector
